

5 June 2024

Company Announcements Office
Australian Securities Exchange

CORIS® Technology Outperforms Manual Cleaning in Biofilm Removal in Endoscopes

Nanosonics (ASX: NAN), a leader in infection prevention solutions, today announced a new study demonstrating that its CORIS technology outperforms manual cleaning in biofilm removal in endoscopes. The study has been accepted for publication in the Journal of Hospital Infection.

<https://www.sciencedirect.com/science/article/pii/S0195670124001993>.

Despite current cleaning and disinfection efforts, flexible endoscopes can remain long-term reservoirs for infectious organisms. Studies have demonstrated that flexible endoscopes are linked to more patient infections than any other reusable medical device. Biofilm contributes significantly to bacterial persistence in endoscope channels. This can lead to the same strain of bacteria being transmitted to multiple patients from contaminated endoscopes over time.

Co-author of the publication, Dr. Michelle Alfa, a world leading expert on biofilm in endoscopes, commented that “these results showing biofilm removal by the CORIS device are significant given the challenges with biofilm in endoscope reprocessing. In particular, the device removed cyclic build up biofilm from the small diameter channels, while the current manual cleaning approach was not effective. New technologies are required to address this significant problem and CORIS represents an opportunity to improve endoscope reprocessing and help prevent endoscope associated infections.”

“The CORIS technology represents a significant opportunity to improve patient safety by addressing what is one of the most significant issues in medical device reprocessing today – the reprocessing of flexible endoscopes. The De Novo regulatory submission to the FDA is currently undergoing review”, said Michael Kavanagh, CEO & President.

Michael Kavanagh
CEO / President

This announcement has been authorised by Matt Carbines, Company Secretary.

For more information, please contact:

Michael Kavanagh, CEO / President or Jason Burriss, CFO on (02) 8063 1600